ContextVision (CONTX) Q1 2025 earnings summary

Executive summary

• Revenue declined 24.2% year-over-year to SEK 26.3 million, mainly due to seasonality, currency effects, and an unfavorable customer mix in Ultrasound.

• Adjusted EBITDA was SEK 2.1 million (8.1% margin), down from SEK 14.0 million (40.3%) last year, reflecting higher investments in Data Quality and FX headwinds.

• Strategic partnerships were signed with the University of Washington, University of Waterloo, and InPhase Solutions to advance digital biomarkers and clinical research for liver disease.

• Strong customer engagement at the European Congress of Radiology in Vienna, with record meetings, contract renewals, and high interest in image quality solutions.

Financial highlights

• Revenue: SEK 26.3 million (Q1 2025) vs. SEK 34.7 million (Q1 2024), -24.2% year-over-year.

• Adjusted EBITDA: SEK 2.1 million (8.1% margin) vs. SEK 14.0 million (40.3%) last year.

• Net result: -SEK 3.1 million vs. SEK 8.6 million last year; adjusted net result: SEK 0.7 million vs. SEK 9.7 million.

• Cash flow from operating activities: SEK 0.3 million (SEK 7.1 million last year); cash at period end: SEK 70.6 million.

• Strengthening of the Swedish krona against USD and EUR negatively impacted EBITDA by almost SEK 4 million year-over-year.

Outlook and guidance

• Short-term market volatility and uncertainty expected, especially regarding currency fluctuations and customer demand.

• Investment levels in Data Quality expected to remain elevated as clinical studies progress.

• Anticipates continued quarterly market fluctuations but aims to build new revenue streams and maintain cash flow control.

• Confident in long-term strategy, expecting gradual revenue growth and additional partnerships as clinical studies progress.